General MedicationsNASALStandard
OPVEE
NALMEFENE HYDROCHLORIDE
Standard Dose
EQ 2.7MG BASE/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview OPVEE is listed in Drugs@FDA under application 217470 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient NALMEFENE HYDROCHLORIDE Form and strength SPRAY;NASAL - EQ 2.7MG BASE/SPRAY Sponsor INDIVIOR Submission history Latest submission status date: 2023-05-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview OPVEE is listed in Drugs@FDA under application 217470 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient NALMEFENE HYDROCHLORIDE Form and strength SPRAY;NASAL - EQ 2.7MG BASE/SPRAY Sponsor INDIVIOR Submission history Latest submission status date: 2023-05-22 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.